scholarly journals Novel vinyl-modified RGD conjugated silica nanoparticles based on photo click chemistry for in vivo prostate cancer targeted fluorescence imaging

RSC Advances ◽  
2019 ◽  
Vol 9 (44) ◽  
pp. 25318-25325
Author(s):  
Hanrui Li ◽  
Ke Li ◽  
Qi Zeng ◽  
Yun Zeng ◽  
Dan Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Click Chemistry ◽  
Silica Nanoparticles ◽  
Fluorescence Imaging ◽  
Tumor Targeting ◽  
Diagnosis And Treatment ◽  
Targeting Ability

Photo click chemistry has been used to prepare RGD conjugated silica nanoprobe (SiO2@T1-RGDk NPs) that exhibits excellent tumor targeting ability and negligible toxicity which enables them to be used for the diagnosis and treatment of cancer.

scholarly journals A Novel TMTP1-modified Theranostic Nanoplatform for Targeted in Vivo NIR-II Fluorescence Imaging-guided Chemotherapy of Cervical Cancer

2021 ◽  
Author(s):  
Alifu Nuernisha ◽  
Rong Ma ◽  
Lijun Zhu ◽  
Zhong Du ◽  
Shuang Chen ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Blood Vessels ◽  
Fluorescence Imaging ◽  
Spatial Resolution ◽  
Self Assembly ◽  
Tumor Targeting ◽  
High Sensitivity ◽  
High Definition ◽  
Targeting Ability

Abstract BackgroundNear-infrared II (NIR-II, 900-1700 nm) fluorescence bioimaging with advantages of good biosafety, excellent spatial resolution, high sensitivity and contrast, has attracted great attentions in biomedical research fields. However, most nanoprobes used for NIR-II fluorescence imaging have poor tumor-targeting ability and therapeutic efficiency. To overcome these limitations, a novel NIR-II-emissive theranostic nanoplatform for imaging and treatment of cervical cancer was designed and prepared. The NIR-II-emissive dye IR-783 and chemotherapy drug doxorubicin (DOX) were encapsulated into liposomes, and the tumor-targeting peptide TMTP1 was conjugated to the surface of the liposomes to form IR-783-DOX-TMTP1 nanoparticles (NPs) via self-assembly methods.ResultsThe IR-783-DOX-TMTP1 NPs showed strong NIR-II emission, excellent biocompatibility, a long lifetime, and low toxicity. Further, high-definition NIR-II fluorescence microscopy images of ear blood vessels and intratumor blood vessels were obtained from IR-783-DOX-TMTP1 NPs-stained mice with high spatial resolution under 808 nm laser excitation. Moreover, IR-783-DOX-TMTP1 NPs showed strong tumor targeting ability and high efficiently chemotherapeutic character towards cervical tumors. ConclusionsThe novel targeting and NIR-II-emissive IR-783-DOX-TMTP1 NPs have potential in diagnosis and therapy for cervical cancer.

scholarly journals Strain-Promoted Azide-Alkyne Cycloaddition-Based PSMA-Targeting Ligands For Multimodal Intraoperative Tumor Detection of Prostate Cancer

2021 ◽  
Author(s):  
Yvonne H.W. Derks ◽  
Mark Rijpkema ◽  
Helene I.V. Amatdjais-Groenen ◽  
Cato Loeff ◽  
Kim E. de Roode ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fluorescence Imaging ◽  
Tumor Targeting ◽  
Solid Phase ◽  
Biodistribution Studies ◽  
Specific Tumor ◽  
Multiple Imaging ◽  
Specific Accumulation ◽  
Modular Platform

Abstract Purpose: Strain-promoted azide-alkyne cycloaddition (SPAAC) is a straightforward and multipurpose conjugation strategy. Use of SPAAC to link different functional elements to prostate specific membrane antigen (PSMA) ligands would facilitate the development of a modular platform for PSMA-targeted imaging and therapy of prostate cancer (PCa). As a first proof-of-concept for the SPAAC chemistry platform we synthesized and characterized four dual-labeled PSMA ligands for intraoperative radiodetection and fluorescence imaging of PCa. Methods: Ligands were synthesized using solid phase chemistry and contained a chelator for 111In or 99mTc labeling. The fluorophore IRDye800CW was conjugated using SPAAC chemistry or conventional N-hydroxysuccinimide (NHS)-ester coupling. LogD values were measured and PSMA-specificity of these ligands was determined in LS174T-PSMA cells. Tumor targeting was evaluated in BALB/c nude mice with subcutaneous LS174T-PSMA and LS174T wildtype tumors using µSPECT/CT imaging, fluorescence imaging, and biodistribution studies. Results: SPAAC chemistry increased lipophilicity of the ligands (range LogD: -2.4 to -4.4). In vivo, SPAAC chemistry ligands showed high and specific accumulation in s.c. LS174T-PSMA tumors up to 24 hours after injection, enabling clear visualization using µSPECT/CT and fluorescence imaging. Overall, no significant differences between the SPAAC chemistry ligands and their NHS-based counterparts were found (2 h p.i., p > 0.05), while 111In-labeled ligands outperformed the 99mTc ligands. Conclusion: Here we demonstrate that our newly developed SPAAC-based PSMA ligands show high PSMA-specific tumor targeting. Use of click-chemistry in PSMA ligand development opens up the opportunity for fast, efficient and versatile conjugations of multiple imaging moieties and/or drugs.

scholarly journals Synthesis of Fluorescent Polythiophene Dots

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Zhen Liu ◽  
Alaa Nahhas ◽  
Li Liu ◽  
Earl Ada ◽  
Xinyu Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hydrazine Hydrate ◽  
Cancer Cells ◽  
Real Time ◽  
Fluorescence Imaging ◽  
Chemical Oxidation ◽  
Prostate Cancer Cells ◽  
One Step ◽  
Live Mouse

Ring-functionalized semiconducting polythiophene dots (Pdots) were synthesized rapidly and in one step by the hydrazine hydrate reduction of doped parent polythiophene, obtained by conventional chemical oxidation of thiophene monomer by FeCl3 in anhydrous acetonitrile. Dispersions of these Pdots display robust (pseudo) solvatochromism and solvatofluorism. Polythiophene Pdots exhibit significant cytotoxicity towards prostate cancer cells (expected) although when injected subcutaneously in vivo in live mouse, no toxicity is observed for 24 days when monitored in real time using fluorescence imaging.

Tumor targeting of functionalized lipid nanoparticles: Assessment by in vivo fluorescence imaging

2010 ◽  
Vol 75 (2) ◽  
pp. 137-147 ◽  
Author(s):  
Mathieu Goutayer ◽  
Sandrine Dufort ◽  
Véronique Josserand ◽  
Audrey Royère ◽  
Emilie Heinrich ◽  
...  
Keyword(s):  
Fluorescence Imaging ◽  
Tumor Targeting ◽  
Lipid Nanoparticles ◽  
In Vivo Fluorescence ◽  
In Vivo Fluorescence Imaging

scholarly journals An internal cross-linked polymeric nanoparticle with dual sensitivity for combination therapy of muscle-invasive bladder cancer

2020 ◽  
Author(s):  
Guanchen Zhu ◽  
Kaikai Wang ◽  
Haixiang Qin ◽  
Xiaozhi Zhao ◽  
Wei Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Cells ◽  
Laser Irradiation ◽  
Tumor Cells ◽  
Tumor Targeting ◽  
Near Infrared ◽  
Infrared Laser ◽  
Infrared Laser Irradiation ◽  
Targeting Ability

Abstract Chemotherapy is a standard cancer treatment which uses anti-cancer drugs to destroy or slow the growth of cancer cells. However, chemotherapy has limited therapeutic effects in bladder cancer. One of the reasons of this resistance to chemotherapy is that higher levels of glutathione in invasive bladder cancer cells. We have fabricated nanoparticles that respond to high concentrations of glutathione and near-infrared laser irradiation in order to increase the drug accumulation at the tumor sites and combine chemotherapy with photothermal therapy to overcome the challenges of bladder cancer treatment.Methods:The DOX&IR780@PEG-PCL-SS NPs were prepared by co-precipitation method. We investigated the tumor targeting capability of NPs in vitro and in vivo. The orthotopic bladder cancer model in C57BL/6 mice was established for in vivo study and the photothermal effects and therapeutic efficacy of NPs were evaluated.Results:The DOX&IR780@PEG-PCL-SS NPs were synthesized using internal cross-linking strategy to increase the stability of nanoparticles. Nanoparticles can be ingested by tumor cells in a short time. The DOX&IR780@PEG-PCL-SS NPs have dual sensitivity to high levels of glutathione in bladder cancer cells and near-infrared laser irradiation. Glutathione triggers chemical structural changes of nanoparticles and preliminarily releases drugs, Near-infrared laser irradiation can promote the complete release of the drugs from the nanoparticles and induce a photothermal effect, leading to destroying the tumor cells. Given the excellent tumor-targeting ability and negligible toxicity to normal tissue, DOX&IR780@PEG-PCL-SS NPs can greatly increase the concentration of the anti-cancer drugs in tumor cells. The mice treated with DOX&IR780@PEG-PCL-SS NPs have a significant reduction in tumor volume. The DOX&IR780@PEG-PCL-SS NPs can be tracked by in vivo imaging system and have good tumor targeting ability, to facilitate our assessment during the experiment.Conclusion:A nanoparticle delivery system with dual sensitivity to glutathione and near-infrared laser irradiation was developed for delivering IR780 and DOX. Chemo-photothermal synergistic therapy of both primary bladder cancer and their metastases was achieved using this advanced delivery system.

scholarly journals In Vivo Tumor Targeting and Image-Guided Drug Delivery with Antibody-Conjugated, Radiolabeled Mesoporous Silica Nanoparticles

ACS Nano ◽  
2013 ◽  
Vol 7 (10) ◽  
pp. 9027-9039 ◽  
Author(s):  
Feng Chen ◽  
Hao Hong ◽  
Yin Zhang ◽  
Hector F. Valdovinos ◽  
Sixiang Shi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Tumor Targeting ◽  
Mesoporous Silica Nanoparticles ◽  
Image Guided ◽  
Image Guided Drug Delivery

A theranostic nanoplatform: magneto-gold@fluorescence polymer nanoparticles for tumor targeting T1&T2-MRI/CT/NIR fluorescence imaging and induction of genuine autophagy mediated chemotherapy

Nanoscale ◽  
2018 ◽  
Vol 10 (22) ◽  
pp. 10467-10478 ◽  
Author(s):  
Guannan Wang ◽  
Kun Qian ◽  
Xifan Mei
Keyword(s):  
Cancer Therapy ◽  
Contrast Agent ◽  
Fluorescence Imaging ◽  
Tumor Targeting ◽  
Polymer Nanoparticles ◽  
Nir Fluorescence ◽  
T2 Mri

Novel contrast agent were designed for in vivo T1&T2-MRI/CT/NIR fluorescence imaging and induction of genuine autophagy-mediated chemosensitization for cancer therapy.

Intravenous, Intraperitoneal, and Subcutaneous Routes of Administering 64Cu-DOTA-HB22.7 Display Equivalent Tumor Targeting Ability.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2359-2359
Author(s):  
Shiloh M. Martin ◽  
Robert T. O’Donnell ◽  
Hayes McKnight ◽  
Julie L. Sutcliff ◽  
Joseph M. Tuscano
Keyword(s):  
Nude Mice ◽  
Tumor Targeting ◽  
Emission Tomography ◽  
New Agents ◽  
Routes Of Administration ◽  
Positron Emission ◽  
Specific Tumor ◽  
Human Lymphoma ◽  
Targeting Ability

Abstract BACKGROUND: Chemotherapy for Non-Hodgkin’s Lymphoma (NHL) is initially effective, but often limited by toxicity and resistance. New agents for the treatment of NHL are needed. HB22.7 is a monoclonal antibody that binds CD22 and has previously been shown to reduce human lymphoma xenograft volume in nude mice. OBJECTIVES: (1) Develop a 64Cu-DOTA-HB22.7 antibody, for in vivo imaging and potential therapy of NHL. (2) Determine if tumor targeting of 64Cu-DOTA-HB22.7 is equivalent between intravenous (IV), intraperitoneal (IP), and subcutaneous (SQ) routes of administration. METHODS: DOTA-HB22.7’s ability to bind CD22+ cells was assessed by flow cytometry. 64Cu-DOTA-HB22.7 was injected IV, IP, or SQ into xenograft-bearing nude mice and tumor targeting assessed by positron emission tomography (PET) and biodistribution assay. Pharmacokinetics were determined by measuring radioactivity of blood samples. Serum was analyzed by radio-TLC. RESULTS: DOTA conjugation does not affect HB22.7’s ability to bind CD22. 64Cu-DOTA-HB22.7 demonstrates specific tumor targeting at 24 and 48 hrs. Targeting is equivalent regardless of route of administration. Pharmacokinetics demonstrate that 64Cu-DOTA-HB22.7 can access the bloodstream (and thus, target tumor) in IP or SQ injections. By 48 hrs, blood 64Cu levels are (a) equivalent, regardless of injection route and (b) below peak levels, indicating clearance from the circulation. Serum analysis shows that right-shifted TLC peaks, possibly 64Cu-DOTA-HB22.7 metabolites, are present only in the IV injected group at 48 hrs. CONCLUSION: These findings establish 64Cu-DOTA-HB22.7 as an NHL-specific imaging agent and indicate its potential for use in radioimmunotherapy. These findings provide evidence that more accessible routes of administration can achieve equivalent targeting results, and may lead to more efficient and accurate administration of antibody-based therapeutics in mice.

Sign in / Sign up

Export Citation Format

Share Document